Caspofungin Acetate is a drug owned by Fresenius Kabi Usa Llc. It is protected by 1 US drug patent filed in 2017 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 21, 2032. Details of Caspofungin Acetate's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9636407 | Caspofungin acetate formulations |
Dec, 2032
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Caspofungin Acetate's patents.
Latest Legal Activities on Caspofungin Acetate's Patents
Given below is the list of recent legal activities going on the following patents of Caspofungin Acetate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Nov, 2020 | US9636407 |
| Recordation of Patent Grant Mailed Critical | 02 May, 2017 | US9636407 |
| Patent Issue Date Used in PTA Calculation Critical | 02 May, 2017 | US9636407 |
| Email Notification Critical | 13 Apr, 2017 | US9636407 |
| Issue Notification Mailed Critical | 12 Apr, 2017 | US9636407 |
| Dispatch to FDC | 29 Mar, 2017 | US9636407 |
| Application Is Considered Ready for Issue Critical | 28 Mar, 2017 | US9636407 |
| Issue Fee Payment Verified Critical | 27 Mar, 2017 | US9636407 |
| Issue Fee Payment Received Critical | 27 Mar, 2017 | US9636407 |
| Mail PUBS Letter Withdrawing a Notice Requiring Inventors Oath or Declaration | 15 Mar, 2017 | US9636407 |
US patents provide insights into the exclusivity only within the United States, but Caspofungin Acetate is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Caspofungin Acetate's family patents as well as insights into ongoing legal events on those patents.
Caspofungin Acetate's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Caspofungin Acetate's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 21, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Caspofungin Acetate Generic API suppliers:
Caspofungin Acetate is the generic name for the brand Caspofungin Acetate. 6 different companies have already filed for the generic of Caspofungin Acetate, with Areva Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Caspofungin Acetate's generic
Alternative Brands for Caspofungin Acetate
There are several other brand drugs using the same active ingredient (Caspofungin Acetate) as Caspofungin Acetate. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Merck |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Caspofungin Acetate, Caspofungin Acetate's active ingredient. Check the complete list of approved generic manufacturers for Caspofungin Acetate
About Caspofungin Acetate
Caspofungin Acetate is a drug owned by Fresenius Kabi Usa Llc. Caspofungin Acetate uses Caspofungin Acetate as an active ingredient. Caspofungin Acetate was launched by Fresenius Kabi Usa in 2016.
Approval Date:
Caspofungin Acetate was approved by FDA for market use on 30 December, 2016.
Active Ingredient:
Caspofungin Acetate uses Caspofungin Acetate as the active ingredient. Check out other Drugs and Companies using Caspofungin Acetate ingredient
Dosage:
Caspofungin Acetate is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG/VIAL | POWDER | Prescription | INTRAVENOUS |
| 70MG/VIAL | POWDER | Prescription | INTRAVENOUS |